September 3rd 2024
Atea pharmaceuticals' oral nucleotide RNA-dependent RNA polymerase inhibitor advances in phase 3 trials for COVID-19 and phase 2 trials for hepatitis C, showing potential efficacy.
Researchers Aim to Eliminate Hepatitis B and C as a Public Health Problem in the United States
April 20th 2016Researchers from the National Academies of Sciences, Engineering, and Medicine report that there is a possibility of eliminating the transmission of both Hepatitis B and C in the United States.
Read More
Hepatitis C Treatment to be Afforded to All Infected Veterans, Regardless of Stage of Disease
March 16th 2016An increase in funding from Congress, in addition to a decrease in drug prices, will allow the VA to finance medical care for all hepatitis C patients, regardless of the stage of the disease, for fiscal year 2016.
Read More
FDA Warns of Serious Slowing of Heart Rate with Hepatitis C Drugs and Amiodarone
May 30th 2015The FDA approved label warning changes for two Gilead Sciences hepatitis C drugs after one person died and nine others had serious reactions when the drugs were coadministered with amiodarone, a drug used to treat irregular heartbeat.
Read More
Reactivation of Hepatitis B Associated With Immunosuppressive Medications
May 30th 2015In patients with chronic HBV, the immune system may have very low levels of the virus. When reactivation occurs due to immunosuppression, these viruses begin to replicate again. Common symptoms of this event include inflammation of the liver and elevations of liver enzyme levels in the blood. In some cases, bilirubin levels may rise in response to reactivation of infection.
Read More
Tenofovir Plus Interferon Improves Antigen Clearance in Chronic Hepatitis B
December 13th 2014Treatment with a combination of tenofovir and pegylated interferon yielded higher rates of hepatitis B surface antigen (HBsAg) loss than when either drug was used singly. Further, with longer therapy duration improved results.
Read More
Triple Therapy for Hepatitis C Infection: Bacterial Infection Risk Rises, Changes
December 1st 2014Patients who have HCV infection are at high risk for arthralgia, myalgias, pruritus, neuropathy, and decompensated livers. Until recently the sole available treatment was interferon. After the US Food and Drug Administration (FDA) approved ribavirin, patients who took ribavirin plus interferon responded better. Now, the FDA has approved a small selection of oral antivirals to treat hepatitis C.
Read More
Recommendations to Improve Liver Health in Hepatitis B, Hepatitis C Patients
September 10th 2014Although it is widely understood that hepatitis B virus (HBV) and hepatitis C virus (HCV) are the leading causes of liver cirrhosis and liver cancer, an alarming number of HBV and HCV carriers have unhealthy habits that result in poor liver health.
Read More
Serious Liver Disease Rates Higher Among Coinfected Patients
June 19th 2014Study results show hepatic decompensation is more common in people who have both HIV and hepatitis C virus (HCV) compared to those infected only with HCV, an indication that early HCV treatment among coinfected patients is needed.
Read More